Trial
NCT02253394
The Combination Ambrisentan Plus Spironolactone in Pulmonary Arterial Hypertension Study
Phase IVTERMINATEDOPERATIONALConfidence: HIGH
Sponsor
Brigham and Women's Hospital
Collaborators
Gilead Sciences
Condition
Pulmonary Arterial Hypertension
Intervention
Ambrisentan plus Spironolactone
Why stopped
Low enrollment
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2019-11-15